Table 2 Issues covered when discussing PSA screening (n = 88a, n (%))
Issue | Never | Rarely | Sometimes | Often | Always |
|---|---|---|---|---|---|
Impact on general mortality | 15 (19.7) | 14 (18.4) | 12 (15.8) | 27 (35.5) | 8 (10.5) |
Impact on disease-specific mortality | 9 (11.8) | 9 (11.8) | 14 (18.4) | 32 (42.1) | 12 (15.8) |
Impact on chances of metastasis | 26 (34.2) | 21 (27.6) | 13 (17.1) | 12 (15.8) | 4 (5.3) |
Overdiagnosis | 1 (1.3) | 3 (3.8) | 10 (12.8) | 34 (43.6) | 30 (38.5) |
False-positive test results | 2 (2.6) | 4 (5.1) | 6 (7.7) | 33 (42.3) | 33 (42.3) |
Anxiety when awaiting test results | 15 (19.5) | 17 (22.1) | 15 (19.5) | 17 (22.1) | 13 (16.9) |
Possibility of further diagnostic tests | 2 (2.6) | 0 (0.0) | 14 (17.9) | 36 (46.2) | 26 (33.3) |
Possible consequences of medical policy b | 2 (2.6) | 3 (3.9) | 11 (14.3) | 41 (53.2) | 20 (26.0) |
Referral to Thuisarts.nl (webpage) c | 4 (5.1) | 8 (10.3) | 19 (24.4) | 34 (43.6) | 13 (16.7) |
Provide handout | 24 (30.8) | 23 (29.5) | 18 (23.1) | 8 (10.3) | 5 (6.4) |